Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

A novel Au-Se nanoplatform for co-delivery of cGAMP and acriflavine synergizes with photothermal therapy to enhance anti-tumor immunity via STING activation and HIF-1α inhibition.

Created on 04 Jul 2026

Authors

Yuanyuan Cui, Yonghui Liang, Huixin Yang, Xudong Wang, Yanjiao Zhang, Guilong Zhang, Renhui Zhan

Published in

Journal of nanobiotechnology. Jul 03, 2026. Epub Jul 03, 2026.

Abstract

Activating the stimulator of interferon genes (STING) pathway is a potent strategy for promoting tumor vascular normalization and enhancing cancer immunotherapy. However, the poor metabolic stability of classical STING agonists limits their clinical translation. Herein, we engineered a self-assembled Au-Se nanoplatform (AAC) for the co-delivery of the STING agonist cyclic 2',3'-GMP-AMP (cGAMP) and the hypoxia-inducible factor-1α (HIF-1α) inhibitor acriflavine (Acf). Upon cellular internalization, the weakly acidic tumor microenvironment (TME) triggers the synchronized release of cGAMP and Acf agents. Next, cGAMP activates the STING pathway to induce type I interferon (IFN-I) production, while Acf disrupts HIF-1α/β dimerization. The activation of STING signal pathway and the inhibition of HIF-1α/β expression synergistically suppress the expression of VEGFA and remodels the TME into an immune-permissive milieu, which promotes vascular normalization and elicits tumor immune response. Combined with the photothermal therapy (PTT) of Au nanorods, AAC induces robust immunogenic cell death (ICD), facilitates dendritic cell (DC) maturation, and enhances cytotoxic T lymphocytes (CTLs) infiltration. In murine breast cancer models, AAC effectively suppressed both primary and distant tumors, highlighting its potential as a versatile nanotherapeutic platform for synergistic photothermal enhanced immunotherapy.

PMID:
42399930
Bibliographic data and abstract were imported from PubMed on 04 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 5
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement